Depósito de pirofosfato de calcio
Pseudogout
Revisado por Dr Toni Hazell, FRCGPÚltima actualización por Dr Philippa Vincent, MRCGPÚltima actualización 30 Jun 2026
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
Profesionales Médicos
Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar el Depósito de pirofosfato de calcio artículo más útil, o uno de nuestros otros artículos de salud.
Antecedentes12
Previously known as pseudogout, calcium pyrophosphate deposition disease (CPPD) is an inflammation of joints caused by the deposition of calcium pyrophosphate (CPP) crystals in articular and periarticular tissues.
Epidemiología34
Calcium pyrophosphate deposition is common in the elderly. Half of adults develop radiographic changes typical of CPPD by the age of 80.
30-50% of patients with CPPD are over the age of 85.4
Most cases of CPPD are non-familial but mutations in the ANK human gene (ANKH) have been demonstrated in some families.5
Due to the low sensitivity of conventional radiography, it is likely that the prevalence of CPPD is underestimated.
Deshidratación.
Intercurrent illness.
Previous surgery or trauma to the joint.
A history of gout.
Family history of CPPD.
Osteoarthritis.
Primary hyperparathyroidism.
Haemochromatosis.
Hypophosphatasia.
Hypomagnesaemia.
Presentación34
CPPD is often asymptomatic, with only radiographic changes of chondrocalcinosis.
Calcium pyrophosphate deposition may cause an acute or chronic arthritis:
Acute CPP crystal arthritis (or pseudogout):
Acute onset of monoarticular or oligoarticular arthritis.
The knee is the most commonly involved joint, followed by the wrist.
Acute attacks of CPPD disease usually settle within 10 days but may last for weeks or months.
Systemic symptoms including fevers, and chills, and constitutional symptoms may occur.
Chronic CPP crystal arthritis:
Most affected patients have a polyarticular form of arthritis that resembles osteoarthritis, but with flares of inflammatory signs and symptoms and by unusually severe articular damage. Involvement of joints such as the glenohumeral joint, wrist, and metacarpophalangeal joints, which are not often affected by typical osteoarthritis, should lead one to suspect CPPD disease.
A rarer form of polyarticular CPPD disease resembles rheumatoid arthritis, with persistent inflammatory arthritis that affects large and small joints. Flares often involve joints sequentially, and involvement is less symmetric than that seen with rheumatoid arthritis.
Diagnóstico diferencial
Investigaciones38
Plain x-ray, ultrasound, CT scan and DECT scans can all be used in the diagnosis of CPPD.
Crystals can be identified on aspiration of the joint fluid.
Manejo8910 11
Unlike gout, there are no specific disease-modifying treatments for the elimination of CPP crystals from the body. Treatment is therefore largely symptomatic, as well as ensuring good management of any underlying metabolic conditions. Care should be tailored to individual patients and should take account of any comorbidities and existing medication regimes.
The European guidelines advice the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids (intra-articular or systemic). The drug of choice will depend on the patient's age and comorbidities.
In 2023, a large study supported the use of prednisolone 30 mg a day as the first line treatment for CPPD. If colchicine is used, initiation in the first 12 hours of symptoms is important.
For chronic CPP crystal arthritis:
Daily colchicine is the preferred first-line treatment, whereas methotrexate and tocilizumab are considered second-line options.47
For patients with monoarticular or oligoarticular large-joint involvement, repeated intra-articular injections of glucocorticoids may control symptoms.
Pronóstico4
Acute attacks often resolve within ten days.
However some acute attacks may last for weeks or months.
Some patients develop progressive joint damage with functional limitation.
Chronic CPPD is characterised by recurrent flare-ups, with symptoms that frequently overlap those of rheumatoid arthritis.
Prognosis will also be dependent on any underlying cause.
Actualizaciones exclusivas para profesionales de la salud
Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Lecturas adicionales y referencias
- Rosenthal AK, Ryan LM; Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016 Jun 30;374(26):2575-84. doi: 10.1056/NEJMra1511117.
- Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate deposition; S Sirotti et al; Annals of the Rheumatic Diseases
- EULAR recommendations for calcium pyrophosphate deposition - Part I: terminology and diagnosis; European League Against Rheumatism (2011)
- Azam A, Minalyan A, Naik R; Calcium Pyrophosphate Deposition Disease.
- Tsui FW; Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6.
- Calcium pyrophosphate deposition disease: The arthropathy formerly known as “Pseudogout”; BPAC NZ
- Calcium pyrophosphate deposition disease; Prof T Pascar et al; The Lancet
- Calcium pyrophosphate dihydrate deposition disease; R Sharma; Radiopedia
- EULAR recommendations for calcium pyrophosphate deposition - Part II Management; European League Against Rheumatism (2011)
- Recent advances in the therapeutic management of calcium pyrophosphate deposition disease; P Voulgari et al; Frontiers in Medicine
- Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review; S Cowley and G McCarthy; Open Access Rheumatology: Research and Reviews
Acerca del revisorVer biografía completa

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
La Dra. Toni Hazell se graduó de la Escuela de Medicina del Hospital St. Mary y realizó su VTS en el Hospital Northwick Park.
Más en reumatología
- Reemplazos de articulación de tobillo
- Espondilitis anquilosante
- Factor de necrosis tumoral alfa anti-tumoral
- Artrogriposis múltiple congénita
- Enfermedades del tejido conectivo durante el embarazo
- Lupus eritematoso discoide
- síndromes de Ehlers-Danlos
- Artritis enteropática
- Distrofia muscular facioescapulohumeral
- Fatiga y CANSANCIO
- Felty's syndrome
- Artritis idiopática juvenil
- Calambres musculares
- Encefalomielitis miálgica
- Fenómenos de sobreuso y RSI
- Precauciones para pacientes con diabetes que se someten a cirugía
- Bursitis prepatelar
- Artritis reactiva
- Artritis reumatoide y el pulmón
- Síndrome de Sjögren


